ClinConnect ClinConnect Logo
Search / Trial NCT02360163

The "Peripheral Access Utilizing Sonographic Evaluation" Study

Launched by HACKENSACK MERIDIAN HEALTH · Feb 9, 2015

Trial Information

Current as of April 24, 2025

Withdrawn

Keywords

ClinConnect Summary

The purpose of this study is to reduce, by using the ultrasound guided technique, the minor surgical procedures that might be required to deliver fluids into the blood of critically ill patients simply because the patients' veins cannot be located through the manual technique.

The ultrasound assisted technique will increase accessibility to small veins that might be missed via the manual technique. The technique of using an ultrasound machine to assist the administration of fluids into a patient's veins is called ultrasound guided peripheral intravenous access (USGPIVA), while the traditio...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • The patient is \>= 21 years of age
  • Adult critically ill patients in CCU and MICU requiring short peripheral intravenous access
  • The patient has been identified as difficult intravenous access (DIVA), defined as at least two failed blind sticks in the antecubital fossa or more distal upper arm veins
  • The patient does not otherwise require a CVC
  • Exclusion Criteria:
  • * The patient has a PICC line on the same side as IV placement and has the following:
  • Has a condition poses risk for DIC, inadequate flow, or infection.
  • Has been identified as a site for "Save the Vein" protocol implementation, unless permission is otherwise obtained by the patient's physician.
  • Has a hemodialysis fistula in place on that upper arm side.
  • * The patient is expected to require therapeutic agent or procedure that necessitates central venous access such as:
  • central venous monitoring
  • Total Parenteral Nutrition
  • Antibiotic requiring central venous access
  • Chemotherapy
  • Vesicants
  • Medications pH less than 5 or more than 9
  • Medications of glucose concentrations above 10%
  • Solution with protein concentrations above 5% (Vascular Access Management, n.d.)
  • The patient already has a central venous catheter access, for reasons other than DIVA, through which therapy can be infused
  • The patient has renal disease and a "Save The Vein" order is anticipated or pending (serum creatinine \>2mg/dL and GFR \<20) for one of the patient's arms, unless permission is otherwise obtained by the patient's physician
  • The patient has a bleeding disorder, unless permission is otherwise obtained by the patient's physician
  • The clinician believes the patient is not a good fit for the study or that the procedure is not appropriate for patient at the given moment

Trial Officials

Nancy Van Buitenen, MSN, APN, RN

Principal Investigator

Hackensack UMC

About Hackensack Meridian Health

Hackensack Meridian Health is a leading healthcare organization based in New Jersey, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical research, Hackensack Meridian Health is committed to fostering collaboration between researchers, healthcare professionals, and patients to develop and evaluate cutting-edge therapies and interventions. With a focus on enhancing health outcomes and addressing pressing medical needs, the organization leverages its extensive network of hospitals, specialty care centers, and research facilities to advance clinical knowledge and contribute to the global body of medical science.

Locations

Hackensack, New Jersey, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials